A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : CIDP / chronic inflammatory demyelinating polyneuropathy

[Related PubMed/MEDLINE]
Total Number of Papers: 1449
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   CIDP  (>> Co-occurring Abbreviation)
Long Form:   chronic inflammatory demyelinating polyneuropathy
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 A population-based study of long-term outcome in treated chronic inflammatory demyelinating polyneuropathy. ---
2020 Abnormality of multimodal evoked potentials in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). EPs
2020 Adjuvant rituximab improves sensory ataxia in CIDP-related Sjogren syndrome. IVIG, SS
2020 An international multicenter efficacy and safety study of IQYMUNE in initial and maintenance treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy: PRISM study. EOS, INCAT, MRC
2020 Antibodies against the node of Ranvier: a real-life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera. ---
2020 Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: Clinical relevance of IgG isotype. Caspr1, CNTN1, EFNS/PNS, IgG, IVIG, Nfasc155
2020 Antibody- and macrophage-mediated segmental demyelination in chronic inflammatory demyelinating polyneuropathy: clinical, electrophysiological, immunological and pathological correlates. ---
2020 Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology. AChR, FAE, LRP4, MG, MuSK, NMJ, NMO, PV
2020 Bendamustine-rituximab (BR) combined therapy for treatment of immuno-mediated neuropathies associated with hematologic malignancy. BR, HM, RFS
10  2020 Chronic immune sensory polyradiculopathy (CISP): First juvenile case description. CISP, SSEP
11  2020 Chronic inflammatory demyelinating polyneuropathy associated with diabetes: a European multicentre comparative reappraisal. ---
12  2020 Chronic Inflammatory Demyelinating Polyneuropathy: Time to Maximal Recovery in Patients Receiving Intravenous Immunoglobulin Therapy. HG, IVIGs, KE
13  2020 Chronic inflammatory demyelinating polyradiculoneuropathy relapse after mexiletine withdrawal in a patient with concomitant myotonia congenita: A case report on a potential treatment option. MC
14  2020 Clinical correlates of fatigue in chronic inflammatory demyelinating polyneuropathy. ---
15  2020 Comparative value and determinants of suitability of outcome measures in treated chronic inflammatory demyelinating polyneuropathy. I-RODS, MRC-SS, ONLS
16  2020 Cranial nerve involvement in typical and atypical chronic inflammatory demyelinating polyneuropathies. DADS, MADSAM
17  2020 Deciphering immune mechanisms in chronic inflammatory demyelinating polyneuropathies. ---
18  2020 Demyelinating polyneuropathy and lymphoplasmacytic lymphoma coexisting in 36-year-old man: A case report. ---
19  2020 Diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy in clinical practice: A survey among Dutch neurologists. EFNS/PNS, IVIG
20  2020 Diagnostic accuracy of MRI and ultrasound in chronic immune-mediated neuropathies. DTI, MMN, MRN, sSMA, STIR
21  2020 Different distribution of demyelination in chronic inflammatory demyelinating polyneuropathy subtypes. MADSAM
22  2020 Distinguish CIDP with autoantibody from that without autoantibody: pathogenesis, histopathology, and clinical features. Caspr1, CNTN1, NF155, NF186
23  2020 Dose Adjustment of Subcutaneous IgG in Chronic Inflammatory Demyelinating Polyneuropathy. SCIG
24  2020 Dramatic clinical response to ultra-high dose IVIg in otherwise treatment resistant inflammatory neuropathies. IVIG, MMNCB
25  2020 Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial. IRRID
26  2020 Efficacy of low dose rituximab in treatment-resistant CIDP with antibodies against NF-155. FTMTRS, NF-155
27  2020 Electrophysiological features of chronic inflammatory demyelinating polyradiculoneuropathy associated with IgG4 antibodies targeting neurofascin 155 or contactin 1 glycoproteins. CNTN1, Nfasc155
28  2020 Electrophysiological Responsiveness to Long-Term Therapy in Chronic Inflammatory Demyelinating Polyneuropathy: Case Report. ---
29  2020 Epidemiology of chronic inflammatory demyelinating polyneuropathy in the South-Eastern area of Santiago, Chile. ---
30  2020 Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. ATTR, PN
31  2020 Fatigue in chronic inflammatory demyelinating polyneuropathy. ---
32  2020 Frequency of diabetes and other comorbidities in chronic inflammatory demyelinating polyradiculoneuropathy and their impact on clinical presentation and response to therapy. MGUS
33  2020 Hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy. CMAP, HSCT, NCV
34  2020 High-Resolution Nerve Ultrasound to Assess Nerve Echogenicity, Fascicular Count, and Cross-Sectional Area Using Semiautomated Analysis. CSA, HRUS, IAR, ICC, IR
35  2020 Hydrocephalus due to marked enlargement of spinal roots in a patient with chronic inflammatory demyelinating polyradiculoneuropathy. ---
36  2020 Immune-mediated inflammatory polyneuropathy overlapping Charcot-Marie-Tooth 1B. CMT, MPZ
37  2020 Immunoadsorption and Plasma Exchange in Seropositive and Seronegative Immune-Mediated Neuropathies. CIS/MS, GBS, IA, IA, IgG, PLEX
38  2020 Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG? FDA's, IVIG, SCIG
39  2020 Immunomodulatory and anti-oxidative effect of the direct TRPV1 receptor agonist capsaicin on Schwann cells. DRG, EAN, MHC-II, SCs
40  2020 Impact of environmental factors and physical activity on disability and quality of life in CIDP. QOL
41  2020 Long-term treatment with subcutaneous immunoglobulin in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a follow-up period up to 7 years. IVIG, LQI, MRC, ONLS, SCIG
42  2020 Low interrater reliability of brachial plexus MRI in chronic inflammatory neuropathies. MMN
43  2020 Membrane property changes in most distal motor axons in chronic inflammatory demyelinating polyneuropathy. ---
44  2020 Monitoring Clinical Course and Treatment Response in Chronic Inflammatory Demyelinating Polyneuropathy During Routine Care: A Review of Clinical and Laboratory Assessment Measures. ---
45  2020 Motor chronic inflammatory demyelinating polyneuropathy (CIDP) in 17 patients: Clinical characteristics, electrophysiological study, and response to treatment. IVIG, MPred-CIDP, PM-CIDP
46  2020 MR neurography of lumbosacral nerve roots: Diagnostic value in chronic inflammatory demyelinating polyradiculoneuropathy and correlation with electrophysiological parameters. CSAs, MRN, ROC, SI
47  2020 MRI quantifies lumbosacral nerve root and sciatic nerve hypertrophy in chronic inflammatory demyelinating polyradiculoneuropathy. ---
48  2020 Nerve dysfunction leads to muscle morphological abnormalities in chronic inflammatory demyelinating polyneuropathy assessed by MRI. MRI
49  2020 Nerve Pathology Distinguishes Focal Motor Chronic Inflammatory Demyelinating Polyradiculoneuropathy From Multifocal Motor Neuropathy. MMN
50  2020 Nerve ultrasound for diagnosing chronic inflammatory neuropathy: a multicenter validation study. CIN, LSS, MMN, NCS
51  2020 Neuraxial Anesthesia and Lower Extremity Peripheral Nerve Blocks for Ankle Surgery in a Patient With Chronic Inflammatory Demyelinating Polyneuropathy: A Case Report. CSE, PNBs
52  2020 Ocrelizumab in a case of refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) with antibodies anti Rituximab. ADA, OCR, RTX
53  2020 Pathological Findings in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Single-Center Experience. ---
54  2020 Pathological spontaneous activity as a prognostic marker in chronic inflammatory demyelinating polyneuropathy. EMG, INCAT-ODSS, PSA
55  2020 Pathophysiology of Chronic Inflammatory Demyelinating Polyneuropathy: Insights into Classification and Therapeutic Strategy. DADS, EFNS/PNS, IVIG, MADSAM
56  2020 Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study. EQ-5D, PATH, QOL, SCIG, TSQM, WPAI-GH
57  2020 Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic review. IgG, PATH, SCIG
58  2020 Progress in Hematopoietic Stem Cell Transplantation for CIDP. HSCT, IVIG
59  2020 Prospective study of the additional benefit of plexus magnetic resonance imaging in the diagnosis of chronic inflammatory demyelinating polyneuropathy. MRI
60  2020 Pulse Oral Corticosteroids in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy. ---
61  2020 Quantitative sudomotor test helps differentiate transthyretin familial amyloid polyneuropathy from chronic inflammatory demyelinating polyneuropathy. ESC, TTR-FAP
62  2020 Randomised trial of intravenous immunoglobulin maintenance treatment regimens in chronic inflammatory demyelinating polradiculoneuropathy. IVIG
63  2020 Rare Occurrence of PLA2R-Positive Membranous Nephropathy in a Patient with Sjogren's Syndrome and CIDP. ---
64  2020 Refractory Chronic Immune-mediated Demyelinating Polyneuropathy. ---
66  2020 Risk factors for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): antecedent events, lifestyle and dietary habits. Data from the Italian CIDP Database. ---
67  2020 Rituximab in refractory chronic inflammatory demyelinating polyneuropathy. INCAT, MRC
68  2020 Safety and Tolerability of Plasma Exchange and Immunoadsorption in Neuroinflammatory Diseases. AEs, GBS, IA, MS, PE, PV
69  2020 Severe CIDP-MGUS responsive to Rituximab. ---
70  2020 Sporadic hereditary neuropathies misdiagnosed as chronic inflammatory demyelinating polyradiculoneuropathy: Pitfalls and red flags. CSF, VUS
71  2020 Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP). ---
72  2020 The Misdiagnosis of CIDP: A Review. ---
73  2020 Therapeutic Plasma Exchange as a Treatment for Autoimmune Neurological Disease. AE, ANDs, GBS, MG, mRS, NMOSD, TPE
74  2020 Treatment-related fluctuations in subacute inflammatory demyelinating polyneuropathy. GBS, SIDP, TRF
75  2020 Unique HLA haplotype associations in IgG4 anti-neurofascin 155 antibody-positive chronic inflammatory demyelinating polyneuropathy. HLA, IgG, NF155
76  2020 Use of Magnetic Resonance Neurography for Evaluating the Distribution and Patterns of Chronic Inflammatory Demyelinating Polyneuropathy. I-RODS, LS, MRN
77  2020 Vagus Nerve Ultrasound in Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Charcot-Marie-Tooth Disease Type 1A. CMT1B, CSAs, HCs
78  2020 What Is in the Literature. ---
79  2020 [Chronic inflammatory demyelinating polyradiculoneuropathy with myelopathy due to massively enlarged nerve roots]. ---
80  2020 [Indication of autologous stem cell transplantation in chronic inflammatory demyelinating polyneuropathy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. AHCT, ENMG, FILNEMUS, MATHEC, SFGM-TC
81  2020 [Pitfalls for Diagnosis of Polyneuropathy by Nerve Conduction Study]. ---
82  2019 A Severe Form of M - protein Negative Distal Acquired Demyelinating Symmetric Neuropathy. DADS, DADS-M
83  2019 Acute-onset chronic inflammatory demyelinating polyneuropathy with anti-neurofascin-155 antibodies and bilateral facial nerve enhancement. ---
84  2019 Anti-Neurofascin-155 IgG4 antibodies prevent paranodal complex formation in vivo. Nfasc155
85  2019 Are the treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) effective and safe? - A Cochrane Overview summary with commentary. ---
86  2019 Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database. DADS, LSS
87  2019 Atypical Clinical Presentations of Pediatric Acute Immune-Mediated Polyneuropathy. AIDP, AMAN, GBS
88  2019 Autoantibodies in chronic inflammatory demyelinating polyradiculoneuropathy. ---
89  2019 Chronic Acquired Polyneuropathy Patient Reported Index (CAPPRI) in chronic inflammatory demyelinating polyradiculoneuropathy. BDI, CAPPRI, FSS, INCAT, MRC-SS
90  2019 Chronic immune sensorimotor polyradiculopathy: Report of a case series. CISMP
91  2019 Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease. ---
92  2019 Chronic inflammatory demyelinating polyneuropathy with anti-NF155 IgG4 in China. NF
93  2019 Chronic Inflammatory Demyelinating Polyneuropathy. MADSAM
94  2019 Chronic inflammatory demyelinating polyneuropathy: a rare cause of falls. ---
95  2019 Chronic inflammatory demyelinating polyneuropathy: Plasmapheresis or cyclosporine can be good treatment options in refractory cases. ---
96  2019 Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment. ---
97  2019 Chronic inflammatory demyelinating polyradiculoneuropathy secondary to immune checkpoint inhibitors in melanoma patients. IVIG
98  2019 Chronic Inflammatory Demyelinating Polyradiculoneuropathy. CSF, IgG4, IVIG
99  2019 Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy. IVIG
100  2019 Clinical and electrophysiological profiles in early recognition of polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes syndrome. POEMS, TLI